VistaGen Therapeutics, Inc. Appoints Mark J. Ginski as Senior Vice President, Head of CMC (Chemistry, Manufacturing and Controls)
February 03, 2021 at 03:44 am IST
Share
On February 1, 2021, Mark J. Ginski, Ph.D. joined VistaGen Therapeutics, Inc. as Senior Vice President, Head of CMC (Chemistry, Manufacturing and Controls). Dr. Ginski joined VistaGen with over 25 years of broad CMC leadership experience, spanning preclinical and clinical development through commercial manufacturing of both drug substance and drug product for small molecules, peptides and biologics. Since September 2020, Dr. Ginski has been acting as a part-time consultant to the Company, providing certain CMC advisory services to the Company. Prior to September 2020, Dr. Ginski served as Vice President, Product Development for ANI Pharmaceuticals from May 2016 to June 2020.
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders. Its pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15, PH80, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines, which are administered as low-dose nasal sprays, are designed with a rapid-onset mechanism of action that activates chemosensory neurons in the nasal cavity and can impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. PH94B is a synthetic investigational pherine from the androstane family.
VISTAGEN THERAPEUTICS, INC. 
